licensingAstraZeneca reunites with Dizal in $1.5bn lung cancer dealAstraZeneca has agreed to pay up to $1.5bn for global rights to Zegfrovy, an EGFR-targeted lung cancer drug developed by Dizal Pharmaceutical – the Chinese biotech it helped create nearly a decade … more ➔
Bayer AGBayerBayer rebuilds pharma while waiting for Monsanto reliefA stronger pipeline and new financing give Bayer room to manoeuvre — but investors are still watching one issue: the US glyphosate litigation. more ➔
Wuxi AppTecChinaWuXi AppTec bets on expansion in EuropeGlobal science, local innovation: In an interview with European Biotech Magazine, WuXi AppTec Co-CEO Steve Yang explains why Europe remains a key source of scientific innovation, why the company continues … more ➔
fundraisingDraig raises $65M Series B as depression trials advanceWelsh biotech Draig Therapeutics has raised an oversubscribed $65 million Series B to accelerate its neuropsychiatry pipeline, taking its total funding to $205 million little more than a year after emerging … more ➔
investmentCriteriaCaixa targets €300M for biotech and tech by 2030Spanish investment holding company CriteriaCaixa plans to invest €300m in early-stage biotechnology and technology companies by 2030 through its two specialist venture funds. more ➔
TechnologyTargeted Protein Degradation: Designed to destroyTargeted protein degradation (TPD) has moved from a highly experimental concept to one of the most closely watched modalities in biopharma. What began with first-generation PROTACs (proteolysis-targeting … more ➔
fundraisingPharmNovo raises €3.5M for phase 2 pain trialSwedish biotech PharmNovo has raised about SEK39m (€3.5m) to help finance a phase 2 study of PN6047, its experimental treatment for neuropathic pain. more ➔
StrategyAB Science cuts three trials in pipeline resetFrench biotech AB Science is discontinuing three masitinib trials as it concentrates its clinical resources on an ALS phase 3 programme and the early-stage development of AB8939 in acute myeloid leu … more ➔
partneringRoche drops two Huntington’s programmes from IonisRoche has discontinued two Huntington’s disease programmes after its Ionis-partnered drug tominersen failed to improve patients’ symptoms and a separate candidate raised concerns in animal studi … more ➔
clinical trialAstraZeneca and Ionis miss in key ATTR-CM trialAstraZeneca and Ionis have suffered a major late-stage setback after Wainua/Wainzua (eplontersen) failed to hit the primary endpoint in a phase 3 trial in transthyretin-mediated amyloid cardiomyopathy … more ➔
Bayer AG
Wuxi AppTec
